Gini Deshpande, PhD, is the founder and CEO of NuMedii, a next-generation drug discovery company that uses advanced data sciences and artificial intelligence technology to rapidly discover new therapeutics. As CEO, she structured critical partnerships with large pharma companies, including Allergan, Astellas, and Aptalis, and raised the initial rounds of financing.

Prior to NuMedii, she helped companies identify optimal markets and whole product solutions for their ground breaking technologies, including Affymetrix (acquired by Thermo Fisher) and iPierian (acquired by Bristol-Myers Squibb). Prior to that, Gini led innovation at Children’s Hospital Boston, the world’s leading pediatric hospital, focused on the creation of new devices for the tiniest patients. Gini has helped commercialize early-stage technologies in research tools, diagnostics and therapeutics and has closed licensing deals worth several million dollars.

Gini received her Masters in Science from the University of Pune (India), her PhD in Biological Sciences from Purdue University, and did post-doctoral work at the Massachusetts General Hospital.